EUVIMEDEUVIMED entdecken
Open Access

Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome

William A Preston iD, Esther Drill iD, Thomas Boerner, Rebecca Gelfer iD, James J Harding iD, Eileen M O'Reilly iD, Andrea Cercek iD, Ghassan Abou-Alfa iD, Wungki Park iD, Vinod P Balachandran, Jeffrey Drebin, Kevin C Soares iD und 4 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po.24.00206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von William A Preston und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Cholangiocarcinoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE This study aimed to define genomic differences between perihilar cholangiocarcinoma (PCA) and distal cholangiocarcinoma (DCA) and identify genomic determinants of survival. MATERIALS AND METHODS Consecutive patients with ECA with tissue for targeted next-generation sequencing were analyzed, stratified by anatomic site (PCA/DCA), disease extent, and treatment. Associations between genomic alterations, clinicopathologic features, and outcomes were analyzed using Cox proportional hazards regression to compare survival. RESULTS In total, 224 patients diagnosed between 2004 and 2022 (n = 127 PCA; n = 97 DCA) met inclusion criteria. The median survival was 29 months (43 after resection and 17 from diagnosis for unresectable disease). Compared with PCA, DCA was enriched in TP53alt (alterations; 69% v 33%; Q < 0.01), epigenetic pathway alterations (45% v 29%; Q = 0.041), and had more total altered pathways (median 3 v 2; Q < 0.01). KRASalt frequency was similar between PCA (36%) and DCA (37%); however, DCA was enriched in KRAS G12D (19% v 9%; P = .002). No other clinicopathologic or genomic variables distinguished subtypes. In resected patients, no genomic alterations were associated with outcome. However, in unresectable patients, CDKN2Aalt (hazard ratio [HR], 2.59 [1.48 to 4.52]) and APCalt (HR, 5.11 [1.96 to 13.3]) were associated with reduced survival. For the entire cohort, irresectability (HR, 3.13 [2.25 to 4.36]), CDKN2Aalt (HR, 1.80 [1.80 to 2.68]), and APCalt (HR, 2.00 [1.04 to 3.87]) were associated with poor survival. CONCLUSION CDKN2Aalt and APCalt were associated with poor survival in ECA, primarily in advanced disease. As PCA and DCA were genetically similar, coanalysis of PCA and DCA in future genomic studies is reasonable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Duct NeoplasmsCholangiocarcinomaHumansMaleFemaleMiddle AgedAgedGenomicsAdultAged, 80 and over

Autor:innen und Institutionen

  • Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medicine, Weill Cornell Medicine, New York, NY.
  • Trinity College Dublin, Dublin, Ireland.
  • The David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: William A Preston, Esther Drill, Rebecca Gelfer, James J Harding, Eileen M O'Reilly, Andrea Cercek, Ghassan Abou-Alfa, Wungki Park, Kevin C Soares, Alice Wei, William R Jarnagin

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Preston, W. A., Drill, E., Boerner, T., Gelfer, R., Harding, J. J., O'Reilly, E. M., Cercek, A., Abou-Alfa, G., Park, W., Balachandran, V. P., Drebin, J., Soares, K. C., Wei, A., Kingham, T. P., D'Angelica, M. I., & Jarnagin, W. R. (2024). Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome. JCO Precision Oncology. https://doi.org/10.1200/po.24.00206

Vancouver

Preston WA, Drill E, Boerner T, Gelfer R, Harding JJ, O'Reilly EM, et al. Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome. JCO Precision Oncology. 2024. doi:10.1200/po.24.00206

BibTeX
@article{Preston2024,
  author = {Preston, William A and Drill, Esther and Boerner, Thomas and Gelfer, Rebecca and Harding, James J and O'Reilly, Eileen M and Cercek, Andrea and Abou-Alfa, Ghassan and Park, Wungki and Balachandran, Vinod P and Drebin, Jeffrey and Soares, Kevin C and Wei, Alice and Kingham, T Peter and D'Angelica, Michael I and Jarnagin, William R},
  title = {Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.24.00206}
}
Kostenlos starten →